Prostate-specific antigen (PSA) is the one of the most valuable tumor markers for the early detection and management of prostate carcinoma, but not an ideal one because of poor specificity in the case of prostatic hypertrophy and other benign conditions. In order to overcome this drawback some other parameters as is free to total ratio (F/T) PSA and PSA density (PSAD) are introduced. It has been investigated in 60 patients, 18 of them are proved to be found prostate cancer and other 42 were identified as benign prostatic hyperplasia. Patients with CaP had TPSA median of 11.4 ng/ml and the others with benign prostatic hyperplasia (BPH) had 6.9 ng/ml. In these two groups there was statistical significant difference (p 0.01). By receiver operating characteristics curve (ROC) estimated cutoff for TPSA was 4.0 ng/ml with 95% sensitivity, 30% specificity and area covered by ROC was in amount of 0.76. Median F/T ratio for patients with prostate cancer was 0.10, and for benign prostatic hyperplasia patients it was 0.25.For these values there is also statistical difference (p). Using ROC cutoff for F/T PSA was determined at the value of 0.18 with sensitivity 95%, specificity 80% and area under the curve (AUC) 0.93. Median for PSAD in the group with CaP was 0.38 and in the BPH group was 0.16. There was statistical significance within those two groups. In conclusion F/T PSA, PSAD and TPSA are valuable tumor markers in distinguishing patients with CaP ant those without with modestly raised TPSA. Also F/T PSA showed up as better marker than TPSA and PSAD in investigated group of patients.
INTRODUCTION
P rostate-specific antigen (PSA) is the one of the most valuable tumor markers for the early detection and management of prostate carcinoma, but not an ideal one because of poor specificity in the case of prostatic hypertrophy and other benign conditions 1 . The reference range of PSA is 4.0 ng/ml However, the presence of elevated PSA level in blood does not confirm the presence of prostate cancer. The value of PSA 4.0 -10.0 ng/ml referred to as the "gray zone" because it appears both with CaP and BPH cases.
Alone TPSA is not capable in distinguishing those two groups. In order to overcome this drawback free to total ratio (F/T PSA) and PSA density (PSAD) -total PSA divided by the prostate volume measured by means of the transrectal ultrasound (TRUS) method are introduced 2 . If the PSAD is greater than 0.15 ng/ml*cm 3 than the presence of tha CaP is probable. Some authors give different values for the F/T PSA cutoff. For the cutoff value of 23.4%, more than 90 % CaPs can be diagnosed 3 .
MATERIAL AND METHODS
The study has included 60 patients with prostatic disease treatment at the Institute of Urology and Nephrology in Belgrade.
The selecting criterion was elevated TPSA level and/or suspicious CaP rectal examination.
All of them are examined on serum TPSA, FPSA, F/T PSA using Abbott Imx tests in the clinical laboratory. Prostate volume has been measured by transrectal ultrasonography (TRUS) and all of them underwent TRUS sextant prostate biopsies. 
RESULTS
Among 60 patients investigated, 18 (30%) of them with the mean age of 69.5 were with biopsy proven prostate cancer, and the other 42 (72% mean age of 67.3) were identified as benign prostatic hyperplasia. The value of TPSA was in the scope of 0.73 to 18.47 ng/ml. Patients with CaP had TPSA median of 11.4 ng/ml and the others with benign prostatic hyperplasia (BPH) had 6.9 ng/ml. In this two groups there was statistical significant difference (p 0.01), because the average TPSA value was greatly higher at the patients with the CaP. By ROC estimated cutoff for TPSA was 4.0 ng/ml with 95% sensitivity, 30% specificity and ROC covered area was 0.76.
Alone FPSA hadn't show statistically significant difference (p> 0.05) between CaP and BPH groups 4 . For patients with CaP, F/T PSA was in the sope of 0.03 to 0.19 with median value of 0.10, and for the BPH ones F/T PSA was in between 0.06 and 0.63 with median 0.25.There was statistical significant difference between those two groups (p< 0.01). F/T PSA 0.18 cutoff with sensitivity 95% and specificity 80% was determined by ROC with 0.93 area under the curve (AUC).
PSAD in the CaP group ranged from 0.11 to 0.87 median 0.38, and in the BPH group from 0.06 to 0.49 median 0.16 with statistical significant difference (p< 0.01), PSAD 0.15 cutoff with 84% sensitivity and 50% specificity and 0.808 AUC.
DISCUSSION
When the ROC areas under the curve (AUC) are compared, it can be seen that the F/T PSA AUC is greater than those for TPSA and PSAD. That shows F/T PSA's superiority over TPSA and PSAD in separation cases with CaP from those without for investigated group of patients. 
SUMMARY
Prostata specifi~ni antigen (PSA) je jedan od najzna~ajnijih tumorskih markera za rano otkrivanje i pra}enje karcinoma prostate, ali ne i idealan zbog toga {to nije specifi~an za karcinom prostate, ve} je specifi~an za sve tipove prostati~nog epitela.
Zbog toga su uvedeni i drugi parametri kao {to je F/T PSA i PSA density (PSAD).
Ukupno je obradjeno 60 pacijenata, 18 sa karcinomom prostate i 42 bez karcinoma.
Kod pacijenata koji su imali karcinom prostate srednja vrednost TPSA iznosila je 11.4 ng/ml, a kod pacijenata bez karcinoma srednja vrednost TPSA iznosila je 6.9 ng/ml.
Izmedju te dve grupe postoji statisti~ki zna~ajna razlika (p< 0.01). Pomo}u ROC krive odredjena je grani~na vrednost za TPSA od 4.0 ng/ml, koja je imala senzitivnost 95%, specifi~nost 30%, a povr{ina ispod ROC krive 0.76.
Srednja vrednost odnosa F/T PSA u grupi pacijenata sa karcinomom prostate iznosila je 0.10, a u grupi bez karcinoma prostate tj. sa benignom prostati~nom hiperplazijom (BPH) 0.25. Izmedju ove dve grupe postoji statisti~ki zna~ajna razlika (p< 0.01). Pomo}u ROC krive odredjena je ta~ka preseka za F/T PSA od 0.18 gde je senzitivnost 95%, specifi~nost 80%, povr{ina ispod ROC krive 0.93. The significance of TPSA free to total PSA ratio and PSA ACI Vol. LIV density in prostate carcinoma diagnostics Srednja vrednost za PSAD u grupi pacijenata sa karcinomom prostate iznosila je 0.38, a u grupi bez karcinoma 0.16. Izmedju ove dve grupe postoji statisti~ki zna~ajna razlika (p< 0.01).
Pomo}u ROC krive odredjena je ta~ka preseka za PSAD od 0.15, gde je senzitivnost 84%, specifi~nost 50%, a povr{ina ispod ROC krive 0.808.
Mo'emo zaklju~iti da F/T PSA, PSA i PSAD pored ukupnog TPSA su zna~ajni parametri u razlikovanju pacijenata sa karcinomom prostate od onih koji ga nemaju kod umereno povi{enih vrednosti TPSA. F/T PSA se pokazao kao superioran parametar u razdvajanju ove dve grupe pacijenata u odnosu na TPSA i PSAD u ispitivanoj grupi pacijenata.
Klju~ne re~i: karcinom prostate, benigna prostati~na hiperplazija, prostata specifi~an antigen, PSA gustina, odnos slobodnog i ukupnog PSA
